Biologics

In August, FDA Commissioner Scott Gottlieb, MD, issued a statement on how the agency will enforce oversight of the stem cell industry moving forward. Dr. Gottlieb noted the FDA is ramping up efforts to prevent dishonest players in the field…

Amgen is investing in Fortuna Fix, a Canadian stem cell company, according to Endpoints News.

A new study published in Clinical Spine Surgery compares posterior cervical spine complications among patients who receive recombinant human bone morphogenetic protein-2 and those who do not.

The spine biologics global market is anticipated to grow at a 2.07 percent compound annual growth rate through 2020, according to a 360 Market Updates report.

Sarah Heilshorn, PhD, a Stanford (Calif.) University associate professor of materials science and engineering, authored a paper in Nature Materials about growing and preserving neural stem cells, according to Stanford News.

Xtant Medical is in a distribution agreement with curasan, a developer of biomaterials and medical device for bone and tissue regeneration.

SeaSpine commercially launched OsteoStrand Demineralized Bone Fibers, with the first implantations occurring in Connecticut and California.

DiscGenics will participate in MedCision's ThawSTAR Early Adopter Program.

Orthofix International updated its fiscal year 2017 earnings guidance, according to The Ledger Gazette.

Pinnacle Spine Group filed an application for FDA clearance of its InFill Lateral Fusion System.